A Double-blind Placebo Controlled, Randomized, Phase II Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients

Trial Profile

A Double-blind Placebo Controlled, Randomized, Phase II Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jul 2018

At a glance

  • Drugs Teslexivir (Primary)
  • Indications Condylomata acuminata
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Anaconda Pharma; Vaxart
  • Most Recent Events

    • 18 Jul 2018 Status changed from active, no longer recruiting to completed.
    • 04 Jun 2018 According to a Vaxart media release, patients are undergoing 3 months follow-up period to assess for condyloma recurrence.
    • 04 Jun 2018 Results presented in a Vaxart media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top